Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
作者： Xiaodong Sun , Shiqi Yang , Jingke Zhao
DOI: 10.2147/DDDT.S97653
关键词:
摘要: As a progressive chronic disease, age-related macular degeneration (AMD) is the leading cause of irreversible vision impairment worldwide. Experimental and clinical evidence has …
paperity.org参考文章(125)
Laura B. Hall, Nazlee Zebardast, John J. Huang, Ron A. Adelman, Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients. Journal of Ocular Pharmacology and Therapeutics. ,vol. 30, pp. 346- 352 ,(2014) , 10.1089/JOP.2013.0188
Leveziel N, Souied Eh, Coscas G, Dragon-Durey Ma, Soubrane G, Benlian P, Richard F, Fremeaux-Bacchi, Y402H Complement factor H polymorphism associated with exudative age-related macular degeneration in the French population Molecular Vision. ,vol. 11, pp. 1135- ,(2005)
Felix Grassmann, Peter Charbel Issa, Diana Pauly, Bernhard H. F Weber, Philipp Herrmann, Frank G Holz, The role of the complement system in age-related macular degeneration. Deutsches Arzteblatt International. ,vol. 111, pp. 133- 138 ,(2014) , 10.3238/ARZTEBL.2014.0133
Da Ru Chi Moon, Dong Kyu Lee, Soon Hyun Kim, Yong Sung You, Oh Woong Kwon, Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor Korean Journal of Ophthalmology. ,vol. 29, pp. 226- 232 ,(2015) , 10.3341/KJO.2015.29.4.226
Daniel F Martin, Maureen G Maguire, GSet al Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe, None, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. ,vol. 364, pp. 1897- 1908 ,(2011) , 10.1056/NEJMOA1102673
Daniel F Martin, Maureen G Maguire, Stuart L Fine, Gui-shuang Ying, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Maryann Redford, Frederick L Ferris 3rd, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, None, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. ,vol. 119, pp. 1388- 1398 ,(2012) , 10.1016/J.OPHTHA.2012.03.053
Shaad E. Abdullah, Roman Perez-Soler, Mechanisms of resistance to vascular endothelial growth factor blockade Cancer. ,vol. 118, pp. 3455- 3467 ,(2012) , 10.1002/CNCR.26540
Mohammad Hossein Yazdi, Mohammad Ali Faramarzi, Shekoufeh Nikfar, Khalil Ghasemi Falavarjani, Mohammad Abdollahi, Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration Expert Opinion on Biological Therapy. ,vol. 15, pp. 1349- 1358 ,(2015) , 10.1517/14712598.2015.1057565
Evangelos S. Gragoudas, Anthony P. Adamis, Emmett T. Cunningham, Matthew Feinsod, David R. Guyer, Pegaptanib for Neovascular Age-Related Macular Degeneration The New England Journal of Medicine. ,vol. 351, pp. 2805- 2816 ,(2004) , 10.1056/NEJMOA042760
Yoshimasa Kuroda, Kenji Yamashiro, Masahiro Miyake, Munemitsu Yoshikawa, Hideo Nakanishi, Akio Oishi, Hiroshi Tamura, Sotaro Ooto, Akitaka Tsujikawa, Nagahisa Yoshimura, Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment A Retrospective Cohort Study Ophthalmology. ,vol. 122, pp. 2303- 2310 ,(2015) , 10.1016/J.OPHTHA.2015.06.053